Needham Reiterates Buy on Solid Biosciences, Maintains $19 Price Target

Needham analyst Gil Blum has reiterated a Buy rating on Solid Biosciences (NASDAQ: SLDB) and maintained a price target of $19 for the company's stock. No additional financial figures or strategic changes were mentioned in the article.